SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Synsorb Biotech

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: The Count who wrote (29)5/15/1997 11:08:00 PM
From: Fred J Bealle   of 32
 
Vincent, you dog! I was at that same meeting. Were you that handsome chap in a tuxedo, who kept nipping from a silver flask at discreet intervals? Was that your wife, that luscious redhead with the stunning decolletage? Was that your pair of pink Borzoi?
I should have recognized you from your postings.

As you said, the meeting was very tame (and genial).
Brad Thompson showed slides that indicated potential:
-annual market for Synsorb Pk of $500 million per year (as you mentioned) and:
-annual market for Synsorb Cd of $1 + billion per year.
($5000 per patient.)
And in response to my question (yes, I was the geek who asked the first question) Brad indicated that there was no COMPETITION, that Syb has a 6 year headstart, and that this is a vein that Syb expects to mine unmolested. (Can you spell "Apotex"? What is a "lawsuit"? Is "naive" a French word?)

On the way out, I stopped to talk to Bob Galler (250,000 shares), who I found to be the originator of the Louise Joy Galler foundation. He looked very pained when he explained that Louise was his daughter. Oops.
Mr. Galler modestly admitted to being involved in Syb from day 1, when he discovered Dr.Armstrong's project results 'on a shelf' at the Alberta Research Council. He was, I believe, instrumental in getting funding for the project to continue, to become visible to the NIH,and to incorporate in 1994.
Since then, he has become very familiar with the NIH, members of the US Congress, and other players in this biomedical saga. A very determined man, who wants to turn a personal tragedy into a medical triumph.
Here are my conclusions from the meeting:
1.the shareholders dress nice (OK)-- their suits cost more than my car
2.they dont ask questions (not OK) or make waves
3.they are very quiet, and mostly aged 25-35.
4.the directors & officers looked competent & mostly sober & smug
5.none of them wore cowboy boots or checkered jackets or had cowshit on their shoes
6.Synsorb is well-run (by really nice, naive people) and deserves a great future

Frederick Bealle
in Willowdale (a poor suburb of Toronto)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext